

MAR 06 2006

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 6, 2006

(use as many sheets as necessary)

Complete if Known

Application Number	09/871,146
Filing Date	5/25/2001
First Named Inventor	Anthony E. BOLTON
Group Art Unit	1649
Examiner Name	Olga Chernyshev
Attorney Docket Number	355908-3053

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BC		2002-0058023	A1	Bolton, et al.	05-16-2002	
		2002-0051771	A1	Bolton, et al.	05-02-2002	
		2003-139466	A1	Peritt, et al.	07-24-2003	
		2003-157073	A1	Peritt, et al.	08-21-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BC		WO	03/045979		Therakos Inc.	06-05-2003		
		WO	98/07436		Vasogen Inc.	02-26-1998		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
BC		BOLTON, "Biological Effects and Basic Science of a Novel Immune-Modulation Therapy," <i>Amer. J. Cardiol.</i> 95(11A):24C-29C (June 6, 2005)	
BC		MAEDA, et al., "Intravenous infusion of syngeneic apoptotic cells by photophoresis induces antigen-specific regulatory T cells." <i>J. Immunol.</i> 174(10):5968-5976 (May 15, 2005)	

Examiner Signature



Date Considered

06/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.